Small Lesion

Small Lesion Detectability #1

Patient History
Patient with history of Melanoma referred to PET/CT for restaging and metastatic evaluation.

Patient BMI
22.6

Acquisition
15 minutes
298 MBq / 8 mCi FDG
96 minute uptake

Conclusion
DISCOVERY MI sensitivity and LightBurst Digital Detector simultaneously provide excellent image quality and resolution. Discovery MI enables greater confidence when looking for small metastatic disease in difficult areas such as the liver.

Courtesy of Stanford University, A. Iagaru, MD

Follow-up contrast enhanced CT confirms the presence of a small lesion detected by Discovery MI's digital PET detection technology.

Small Lesion Detectability #2

Patient History
Patient with history of Head and Neck cancer referred to PET/CT to evaluate extent of disease and lymph node involvement.

Patient BMI
25.6

Acquisition
2 minutes / FOV
329 MBq / 8.9 mCi FDG
65 minute uptake

Conclusion
Discovery MI sensitivity and LightBurst Digital Detector simultaneously provide excellent image quality and resolution. Discovery MI provides excellent small lesion detectability for assessing small lymph node involvement in the Head and Neck area.

Courtesy University of Zurich


Small Lesion Detectability #3

Patient History
Patient with history of Prostate cancer referred to PET/CT with new bone pain. Evaluation of metastatic disease.

Patient BMI
27.4

Acquisition
25 minutes
270 MBq / 7.3 mCi 18F - NAF
113 minute uptake

Conclusion
Discovery MI sensitivity and clinical resolution provide small lesion detectability for small bone lesions.

Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.


Small Lesion Detectability #4

Low noise imaging demonstrates excellent image quality / small lesion detectability.

Courtesy Stanford University, A. Iagaru, MD. PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Advanced CT

Advanced CT

Patient History
Patient referred to PET/CT for evaluation of bone formation around prothesis and assessment of inflammation.

Acquisition
298 MBq / 8 mCi NaF
96 minute uptake
CT Reconstruction with Smart MAR
PET Reconstruction with Q.Clear

Courtesy PET Center Uppsala

High Count Rate Tracers

High Count Rate Tracers #1

Patient History:
73-year-old patient with history of
HTN, DM and CAD with prior LAD PCI
and Stent. Referred to PET/CT for
dyspnea and chest heaviness.

Patient BMI:
27.8

Acquisition:
20 minute dynamic 13N-Ammonia
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest

Courtesy Stanford University, G. Davidzon, MD



High Count Rate Tracers #2

Patient History:
Patient referred to Cardiac PET/CT to evaluate chest pain. No history of previous CAD.

Acquisition:
5 minute 15O-Water
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest

Findings
Proximal LAD shows 54% stenosis on CTA which corresponds to anteroseptal perfusion defect on PET.

Courtesy of Uppsala University PET Center



Cardiac

Cardiac #1

Patient History:
Patient referred to PET/CT for
evaluation of Coronary Artery Disease.

Patient BMI:
28.1

Acquisition:
20 minute dynamic 13N - Ammonia
200 MBq / 5.4 mCi Stress
400 MBq / 10.8 mCi Rest

Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.


Cardiac #2

Patient History:
73-year-old patient with history of
HTN, DM and CAD with prior LAD PCI
and Stent. Referred to PET/CT for
dyspnea and chest heaviness.

Patient BMI:
27.8

Acquisition:
20 minute dynamic 13N-Ammonia
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest

Courtesy Stanford University, G. Davidzon, MD



Cardiac #3

Patient History:
Patient referred to Cardiac PET/CT to evaluate chest pain. No history of previous CAD.

Acquisition:
5 minute 15O-Water
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest

Findings
Proximal LAD shows 54% stenosis on CTA which corresponds to anteroseptal perfusion defect on PET.

Courtesy of Uppsala University PET Center



Cardiac #4

Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.

Patient BMI:
25.2

Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake

Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Fast Scans

Fast Scans #1

½ Time1, No Compromise.
Discovery MI sensitivity and LightBurst Digital Detector provide reliable and consistent image quality, resolution and quantitative accuracy. With Discovery MI, a research center can free up scanner time for its studies without impacting daily clinical workload.

Courtesy Stanford University, A. Iagaru, MD
1Compared to Discovery PET/CT 710


Fast Scans #2

Patient History
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.

Patient BMI
28.4

Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake

Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.



Fast Scans #3

Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.

Patient BMI:
25.2

Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake

Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Low Dose

Low Dose #1

Patient History:
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.

Patient BMI
28.4

Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake

Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Low Dose #2

Patient History:
Patient referred to PET/CT for
evaluation of Coronary Artery Disease.

Patient BMI:
28.1

Acquisition:
20 minute dynamic 13N - Ammonia
200 MBq / 5.4 mCi Stress
400 MBq / 10.8 mCi Rest

Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Low Dose #3

Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.

Patient BMI:
25.2

Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake

Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.





Low Dose #4

Ga-68 DOTATATE

Left
- 78 minute uptake
- 2.6 mCi / 96 MBq at scan time

Right
- 104 minute uptake
- 2.2 mCi / 81 MBq at scan time

Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.




Low Dose #5

Patient History
Patient with history of HCC treated with Y-90 TheraSpheres. PET/CT for post-treatment verification.

Patient BMI
20.6

Acquisition
15 minute scan
Y-90 TheraSpheres
91.94 mCi / 3.4 GBq

Courtesy Stanford University, S. Srinivas, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.

Neurology

Neurology #1

Patient History
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.

Patient BMI
28.4

Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake

Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.



Neurology #2

Patient History:
Patient referred to PET/CT for
evaluation of Parkinson's disorders.

Acquisition
11C-PE21-dynamic
study

Courtesy PET Center Uppsala.
PET Radiopharmaceutical may not be approved by ministers of health in all regions.